memantine

Summary

Summary: AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.

Top Publications

  1. ncbi Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse
    Chris G Parsons
    Merz Pharmaceuticals, Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany
    Neuropharmacology 53:699-723. 2007
  2. ncbi Donepezil and memantine for moderate-to-severe Alzheimer's disease
    Robert Howard
    Institute of Psychiatry, King s College London, London SE5 8AF, United Kingdom
    N Engl J Med 366:893-903. 2012
  3. pmc Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses
    Peng Xia
    Del E Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford Burnham Medical Research Institute, La Jolla, California 92037, USA
    J Neurosci 30:11246-50. 2010
  4. ncbi The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model
    M Bond
    Peninsula Technology Assessment Group PenTAG, University of Exeter, Exeter, UK
    Health Technol Assess 16:1-470. 2012
  5. ncbi Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors
    F Leveille
    UMR 6232 Centre National de la Recherche Scientifique Université de Caen, GIP Cyceron, Bd Henri Becquerel, BP 5229 14074 Caen, France
    FASEB J 22:4258-71. 2008
  6. pmc Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome
    Jason Lockrow
    Department of Neuroscience, Center on Aging, Medical University of South Carolina, 173 Ashley Avenue, Ste 410D, Charleston, SC 29425, USA
    Behav Brain Res 221:610-22. 2011
  7. ncbi Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test
    Alberto C S Costa
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    Neuropsychopharmacology 33:1624-32. 2008
  8. ncbi Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease
    Rimante Minkeviciene
    Department of Neuroscience and Neurology, University of Kuopio, P O Box 1627, 70211 Kuopio, Finland
    J Pharmacol Exp Ther 311:677-82. 2004
  9. pmc Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults
    Stuart A Lipton
    The Burnham Institute, and the University of California, San Diego, La Jolla, California 92037, USA
    NeuroRx 1:101-10. 2004
  10. ncbi Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats
    Jyotirmoy Kusari
    Department of Biological Sciences, Allergan Inc, Irvine, CA 92623 9534, USA
    Invest Ophthalmol Vis Sci 48:5152-9. 2007

Detail Information

Publications327 found, 100 shown here

  1. ncbi Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse
    Chris G Parsons
    Merz Pharmaceuticals, Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany
    Neuropharmacology 53:699-723. 2007
    ..b>Memantine received marketing authorization from the EMEA (European Medicines Agency) for the treatment of moderate to ..
  2. ncbi Donepezil and memantine for moderate-to-severe Alzheimer's disease
    Robert Howard
    Institute of Psychiatry, King s College London, London SE5 8AF, United Kingdom
    N Engl J Med 366:893-903. 2012
    ..Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease...
  3. pmc Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses
    Peng Xia
    Del E Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford Burnham Medical Research Institute, La Jolla, California 92037, USA
    J Neurosci 30:11246-50. 2010
    ..b>Memantine, an adamantane derivative, has been used for the treatment of Alzheimer's disease with an excellent clinical ..
  4. ncbi The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model
    M Bond
    Peninsula Technology Assessment Group PenTAG, University of Exeter, Exeter, UK
    Health Technol Assess 16:1-470. 2012
    ..Alzheimer’s disease (AD) is the most commonly occurring form of dementia. It is predominantly a disease of later life, affecting 5% of those over 65 in the UK...
  5. ncbi Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors
    F Leveille
    UMR 6232 Centre National de la Recherche Scientifique Université de Caen, GIP Cyceron, Bd Henri Becquerel, BP 5229 14074 Caen, France
    FASEB J 22:4258-71. 2008
    ..Finally, we demonstrated that the only clinically approved NMDAR antagonist, memantine, preferentially antagonizes extrasynaptic NMDARs...
  6. pmc Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome
    Jason Lockrow
    Department of Neuroscience, Center on Aging, Medical University of South Carolina, 173 Ashley Avenue, Ste 410D, Charleston, SC 29425, USA
    Behav Brain Res 221:610-22. 2011
    b>Memantine is a partial NMDA receptor antagonist that has been shown to improve learning and memory in several animal models, and is approved for the treatment of Alzheimer's disease (AD)...
  7. ncbi Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test
    Alberto C S Costa
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    Neuropsychopharmacology 33:1624-32. 2008
    ..Furthermore, we have found that acute injections (5 mg/kg, i.p.) of the uncompetitive NMDAR antagonist memantine rescue performance deficits of Ts65Dn mice on a fear conditioning test...
  8. ncbi Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease
    Rimante Minkeviciene
    Department of Neuroscience and Neurology, University of Kuopio, P O Box 1627, 70211 Kuopio, Finland
    J Pharmacol Exp Ther 311:677-82. 2004
    b>Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate receptor antagonist, has been shown to improve learning and memory in several pharmacological models of Alzheimer's disease (AD)...
  9. pmc Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults
    Stuart A Lipton
    The Burnham Institute, and the University of California, San Diego, La Jolla, California 92037, USA
    NeuroRx 1:101-10. 2004
    ..In contrast, studies in my laboratory were the first to show that memantine, an adamantane derivative, preferentially blocks excessive NMDA receptor activity without disrupting normal ..
  10. ncbi Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats
    Jyotirmoy Kusari
    Department of Biological Sciences, Allergan Inc, Irvine, CA 92623 9534, USA
    Invest Ophthalmol Vis Sci 48:5152-9. 2007
    To test whether chronic memantine (MEM) treatment improves retinal function and prevents neurodegeneration and vascular changes in the retinas of streptozotocin (STZ)-induced diabetic rats.
  11. ncbi Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review
    Dimitris Repantis
    Department of Psychiatry, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany
    Pharmacol Res 61:473-81. 2010
    ..g. acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Based on a systematic review we found that expectations about the potential of these drugs exceed their actual ..
  12. ncbi Lack of evidence for the efficacy of memantine in mild Alzheimer disease
    Lon S Schneider
    University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Arch Neurol 68:991-8. 2011
    We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD)...
  13. pmc Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes
    David C Wrighton
    Centre for Neuroscience Research, Hugh Robson Building, University of Edinburgh, George Square, Edinburgh, UK
    J Physiol 586:211-25. 2008
    ..receptors (NMDARs) display differences in their sensitivity to the channel blockers Mg(2+) and memantine that are dependent on the identity of the NR2 subunit present in the receptor-channel complex...
  14. ncbi Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
    S Gauthier
    MCSA Alzheimer s Disease Research Unit, McGill Centre for Studies in Aging, Quebec, Canada
    Int J Geriatr Psychiatry 20:459-64. 2005
    ..We have analysed the databases of two randomised studies with regard to the effects of memantine treatment on behavioural symptoms, measured using the 12-item version of the Neuropsychiatric Inventory (NPI).
  15. ncbi The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801
    G Rammes
    Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstr 2, 80804 Munich, Germany
    Neuropharmacology 40:749-60. 2001
    ..was examined in vivo in rats, and compared to two effective non-competitive NMDA-receptor antagonists, memantine and MK-801. Electrophysiology in cultured hippocampal neurons (IC(50) approx. 5...
  16. ncbi Mechanism of action of memantine
    Jon W Johnson
    Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
    Curr Opin Pharmacol 6:61-7. 2006
    b>Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's disease...
  17. pmc Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
    Paul D Brown
    Corresponding Author Paul D Brown, MD, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030
    Neuro Oncol 15:1429-37. 2013
    To determine the protective effects of memantine on cognitive function in patients receiving whole-brain radiotherapy (WBRT).
  18. ncbi Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol
    Carsten Culmsee
    Institut fur Pharmakologie und Toxikologie, Philipps Universitat, Marburg, Germany
    Stroke 35:1197-202. 2004
    ..Therefore, we chose memantine and clenbuterol, both approved safe and efficient in their respective therapeutical categories, and examined ..
  19. ncbi Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine
    Fernanda G De Felice
    Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208, USA
    J Biol Chem 282:11590-601. 2007
    ..b>Memantine, an open channel NMDA-R antagonist prescribed as a memory-preserving drug for AD patients, completely protected ..
  20. pmc Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study
    Jon E Grant
    Department of Psychiatry, University of Minnesota School of Medicine, 2450 Riverside Avenue, Minneapolis, MN 55454, USA
    Psychopharmacology (Berl) 212:603-12. 2010
    Although pathological gambling (PG) is relatively common, pharmacotherapy research for PG is limited. Memantine, an N-methyl D-aspartate receptor antagonist, appears to reduce glutamate excitability and improve impulsive decision making, ..
  21. ncbi Memantine: a review of its use in moderate to severe Alzheimer's disease
    Kate McKeage
    Adis, Auckland, New Zealand
    CNS Drugs 23:881-97. 2009
    b>Memantine is an uncompetitive, moderate-affinity NMDA receptor antagonist that is indicated for the treatment of moderate to severe Alzheimer's disease...
  22. ncbi Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease
    Jean Lachaine
    University of Montreal, Quebec
    Can J Psychiatry 56:596-604. 2011
    An observational study showed that combining memantine with a cholinesterase inhibitor (ChEI) treatment significantly delayed admission to nursing homes in patients with Alzheimer disease (AD)...
  23. ncbi Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers
    Claudia P Figueiredo
    School of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944 590, Brazil
    J Neurosci 33:9626-34. 2013
    ..On the other hand, HMW oligomers, but not LMW oligomers, induced oxidative stress in hippocampal neurons. Memantine rescued both neuronal oxidative stress and the transient memory impairment caused by HMW oligomers, but did not ..
  24. ncbi Pathologically activated therapeutics for neuroprotection
    Stuart A Lipton
    Burnham Institute for Medical Research, The Salk Institute for Biological Studies, The Scripps Research Institute, and the University of California at San Diego 10901 North Torrey Pines Road, La Jolla, California 29, 037, USA
    Nat Rev Neurosci 8:803-8. 2007
    ..This approach has already met with success, and has led to the development of the potentially neuroprotective drug memantine, an N-methyl-D-aspartate (NMDA)-type and glutamate receptor antagonist.
  25. pmc Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections
    Wojciech Danysz
    Merz Pharmaceuticals GmbH, Eckenheimer Landstraße, Frankfurt am Main, Germany
    Br J Pharmacol 167:324-52. 2012
    ..Strong support for the clinical relevance of such interactions is provided by the NMDA receptor antagonist memantine. This substance is the only NMDA receptor antagonist used clinically in the treatment of AD and therefore offers ..
  26. ncbi Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Alzheimer Dis Assoc Disord 20:23-9. 2006
    b>Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, is currently the only agent approved for moderately severe to severe Alzheimer disease (AD) in Europe and for moderate-to-severe Alzheimer disease in ..
  27. pmc Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine
    S Rosi
    Brain and Spinal Injury Center, University of California, San Francisco, CA, USA
    Brain 132:2464-77. 2009
    ..Low doses of memantine, a low to moderate affinity open channel uncompetitive N-Methyl-d-aspartate receptor antagonist, reduce ..
  28. pmc Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine
    Jonah J Scott-McKean
    Neuroscience Training Program, University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA
    Learn Mem 18:774-8. 2011
    ..In addition, this abnormal level of LTD can be pharmacologically rescued by the NMDA receptor antagonist memantine.
  29. pmc Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice
    Hilda Martinez-Coria
    Department of Neurobiology and Behavior, University of California, Irvine, 3400A Biological Sciences III, Irvine, CA 92697 4545, USA
    Am J Pathol 176:870-80. 2010
    b>Memantine is an N-methyl-d-aspartate receptor antagonist that is approved for the treatment of moderate to severe Alzheimer's disease (AD)...
  30. ncbi Dose-related effects of memantine on a mismatch negativity-like response in anesthetized rats
    D Tikhonravov
    Neuroscience Unit, Institute of Biomedicine Physiology, University of Helsinki, Helsinki, Finland
    Neuroscience 167:1175-82. 2010
    b>Memantine is a low-affinity NMDA receptor antagonist that is used in the treatment of Alzheimer's disease to alleviate the cognitive symptoms of the disease...
  31. ncbi Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
    Marisa Hanney
    Wolfson Centre for Age Related Diseases, King s College London, London, UK
    Lancet 379:528-36. 2012
    ..Evidence to support treatment with Alzheimer's drugs is inadequate, although memantine is beneficial in transgenic mice...
  32. pmc NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia
    Simon M Manning
    Department of Neurology, Children s Hospital, Boston, Massachusetts 02115, USA
    J Neurosci 28:6670-8. 2008
    ..The expression pattern mirrors that seen in the immature rat. Furthermore, the uncompetitive NMDAR antagonist memantine attenuates NMDA-evoked currents in developing OLs in situ in cerebral white matter of immature rats...
  33. ncbi Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine
    Igor Klyubin
    Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
    Neurobiol Aging 32:614-23. 2011
    ..Here, the ability of the NMDA receptor (NMDAR) antagonist memantine to prevent synthetic Aβ-mediated rapid functional deficits in learned behavior and synaptic plasticity was ..
  34. pmc Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
    O L Lopez
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Neurol Neurosurg Psychiatry 80:600-7. 2009
    ..There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD)...
  35. pmc Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging
    Henrieta Scholtzova
    Department of Neurology, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci Res 86:2784-91. 2008
    b>Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to improve learning and memory in several preclinical models of Alzheimer's disease (AD)...
  36. ncbi Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons
    Yasco Aracava
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, 655 West Baltimore St, Baltimore, MD 21201, USA
    J Pharmacol Exp Ther 312:1195-205. 2005
    The N-methyl-d-aspartate (NMDA) receptor antagonist memantine is an approved drug for treatment of Alzheimer's disease (AD)...
  37. ncbi Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro
    Saffar Mansoor
    Department of Ophthalmology, School of Medicine, University of California, Irvine, United States
    Toxicology 271:107-14. 2010
    ..catechol (a component from cigarette smoke) on Müller cells (MIO-M1) in vitro, and investigates the inhibitors memantine and epicatechin to determine if they can reverse the catechol toxic effects...
  38. pmc Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study
    Lidia Glodzik
    Center for Brain Health, Department of Psychiatry, New York University New York, NY 10016, USA
    Prog Neuropsychopharmacol Biol Psychiatry 32:1005-12. 2008
    Glutamate (Glu) is associated with excitotoxic cell damage. Memantine modulates the glutamate induced excitotoxicity in Alzheimer's disease (AD)...
  39. ncbi Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients
    Jean Sébastien Vidal
    Institut National de la Santé et de la Recherche Médicale INSERM U708, Paris, France
    Alzheimer Dis Assoc Disord 22:125-30. 2008
    Clinical trials have shown modest effects of memantine, an N-methyl-D aspartate receptor antagonist, in Alzheimer disease patients and memantine effectiveness in routine clinical practice needs to be established further...
  40. pmc Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?
    Jill M Recla
    IGERT Program in Functional Genomics, The University of Maine, Orono ME 04469, USA
    Med Hypotheses 73:177-83. 2009
    ..This article proposes a combined treatment of pregabalin and memantine to decrease the pain and rate of gray matter atrophy associated with FMS...
  41. ncbi Carbofuran-induced oxidative stress in slow and fast skeletal muscles: prevention by memantine and atropine
    Dejan Milatovic
    University Washington, Seattle, WA, USA
    Toxicology 208:13-24. 2005
    ..In addition, we aimed to determine if memantine HCl (MEM), in combination with atropine sulfate (ATS), prevents carbofuran-induced changes in markers of ..
  42. ncbi Low doses of memantine disrupt memory in adult rats
    Catherine Creeley
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Neurosci 26:3923-32. 2006
    b>Memantine, a drug recently approved for treatment of Alzheimer's disease, has been characterized as a unique NMDA antagonist that confers protection against excitotoxic neurodegeneration without the serious side effects that other NMDA ..
  43. ncbi Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
    Dag Aarsland
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, 4068 Stavanger, Norway
    Lancet Neurol 8:613-8. 2009
    ..We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine in patients with PDD or DLB.
  44. pmc Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina
    Won Kyu Ju
    Hamilton Glaucoma Center, University of California San Diego, La Jolla, California 92037, USA
    Invest Ophthalmol Vis Sci 50:707-16. 2009
    ..expression and triggers OPA1 release, as well as whether the uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist memantine blocks OPA1 release and subsequent apoptotic cell death in glaucomatous DBA/2J mouse retina.
  45. ncbi Memantine attenuates staurosporine-induced activation of caspase-3 and LDH release in mouse primary neuronal cultures
    Danuta Jantas-Skotniczna
    Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31 343 Krakow, Poland
    Brain Res 1069:145-53. 2006
    ..In order to further elucidate this problem, we investigated effect of memantine, an uncompetitive NMDA receptor antagonist and staurosporine alone and in combination on caspase-3 activity and ..
  46. ncbi A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease
    Simona Gabriella Di Santo
    Fondazione IRCCS Santa Lucia, Roma, Italy
    J Alzheimers Dis 35:349-61. 2013
    Randomized clinical trials have evaluated the efficacy of acetylcholinesterase inhibitors (AChE-Is) and memantine across a wide range of Alzheimer's disease (AD) severity...
  47. ncbi No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use
    G L Wenk
    Division of Neural Systems, Memory and Aging, University of Arizona, Tucson 85724, USA
    Life Sci 66:1079-83. 2000
    ..g. galanthamine, tetrahydroaminoacridine or donepezil, or by attenuation of NMDA receptor function, e.g. memantine. A combination of these two therapeutic approaches may be more beneficial at slowing the progression of the AD...
  48. ncbi The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence
    Gabriele Sani
    NESMOS Department Neurosciences, Mental Health, and Sensory Organs, School of Medicine and Psychology, Sapienza University, UOC Psychiatry, SantAndrea Hospital, Rome, Italy
    CNS Drugs 26:663-90. 2012
    b>Memantine, a non-competitive NMDA receptor antagonist approved for Alzheimer's disease with a good safety profile, is increasingly being studied in a variety of non-dementia psychiatric disorders...
  49. ncbi Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX 07730, USA
    Dement Geriatr Cogn Disord 33:164-73. 2012
    ..mg/day versus donepezil 10 mg/day for moderate-to-severe Alzheimer's disease allowed patients taking concomitant memantine. We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant ..
  50. ncbi Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study
    Cedric Annweiler
    Department of Neuroscience, Division of Geriatric Medicine, Angers University Hospital, Angers, France
    Cogn Behav Neurol 25:121-7. 2012
    To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD).
  51. ncbi Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Parkinsonism Relat Disord 17:156-9. 2011
    To perform an exploratory study evaluating memantine for several common non-motor problems in Parkinson's disease.
  52. ncbi The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia
    Victoria Larsson
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Sweden
    Int J Geriatr Psychiatry 25:1030-8. 2010
    ..This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on the sleep disturbances in DLB and PDD patients.
  53. ncbi Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine
    Carolyn Paul
    Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
    J Pharmacol Exp Ther 302:50-7. 2002
    ..The current investigation has used the NMDA receptor antagonist memantine to modify the neurological course of EAE and, in particular, prevent BBB breakdown...
  54. pmc MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia
    J W Ashford
    War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, CA, USA
    J Alzheimers Dis 26:331-6. 2011
    ..b>Memantine is thought to benefit the AD brain by stabilizing the NMDA receptors on neurons in turn reducing excitotoxicity...
  55. ncbi N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease
    David Olivares
    Service of Clinical Pharmacology, Hospital Clinico San Carlos, C Professor Martín Lagos s n, 28040, Madrid, Spain
    Curr Alzheimer Res 9:746-58. 2012
    b>Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for moderate to severe Alzheimer's disease (AD) treatment within the U.S...
  56. ncbi Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones
    A R Wild
    Department of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge CB2 3DY, UK
    Neuropharmacology 73:138-46. 2013
    ..The open channel NMDAR blocker, memantine is used to treat certain neurodegenerative diseases, including Parkinson's disease (PD) and is well tolerated ..
  57. pmc Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats
    Shawn E Kotermanski
    Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Pharmacol Biochem Behav 109:67-76. 2013
    b>Memantine and ketamine block N-methyl-D-aspartate (NMDA) receptors with similar affinity and kinetics, yet their behavioral consequences differ: e.g...
  58. ncbi Memantine in moderate-to-severe Alzheimer's disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York 10016, USA
    N Engl J Med 348:1333-41. 2003
    Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease.
  59. ncbi Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP
    W Zajaczkowski
    Department of Pharmacology, Merz and Co, Frankfurt M, Germany
    Neuropharmacology 36:961-71. 1997
    ..maleate (MK-801) and 1-amino-3,5-dimethyladamantane (memantine), starting at low doses of 0.05 and 2.5 mg/kg, respectively, in a bell-shaped dose-response relationship...
  60. ncbi Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
    Murat Emre
    Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
    Lancet Neurol 9:969-77. 2010
    ..with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed...
  61. pmc False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine
    Carola Romberg
    Department of Experimental Psychology, University of Cambridge, Cambridge CB2 3EB, UK
    Brain 135:2103-14. 2012
    ..recognition did not occur when mice were treated with the partial N-methyl-d-aspartic acid receptor antagonist memantine. In a subsequent experiment, we found abnormally enhanced N-methyl-d-aspartic acid receptor-dependent long-term ..
  62. ncbi The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
    Sarah Thompson
    Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Expert Opin Drug Saf 3:425-40. 2004
    ..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine.
  63. pmc Antitussive effects of memantine in guinea pigs
    Jaclyn A Smith
    Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA
    Chest 141:996-1002. 2012
    ..Based on evidence supporting a role for N-methyl D-aspartate receptors (NMDARs) in cough, we hypothesized that memantine, a low-affinity, uncompetitive NMDAR channel blocker in routine use for the treatment of Alzheimer disease, ..
  64. ncbi Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease
    Mohammed Filali
    Laboratory of Endocrinology and Genomics, CHUQ Research Center and Department of Molecular Medicine, Laval University, 2705 Boulevard Laurier, Quebec G1V 4G2, Canada
    Neuropharmacology 60:930-6. 2011
    ..in Alzheimer pathogenesis, with clinical data supporting successful treatment with the NMDA receptor antagonist memantine. In the present study, the effects of subchronic memantine administration were assessed on spatial and non-..
  65. ncbi A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Neuropsychopharmacology 34:1322-9. 2009
    b>Memantine, an uncompetitive antagonist of glutamate receptors of the N-methyl-D-aspartate type is approved for the treatment of moderate to severe Alzheimer's disease...
  66. ncbi Randomized controlled trial of memantine in dementia associated with Parkinson's disease
    Iracema Leroi
    Lancashire Care Trust, Royal Blackburn Hospital, Blackburn, United Kingdom
    Mov Disord 24:1217-21. 2009
    The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD...
  67. ncbi Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model
    Teresa Ponce-Lopez
    Departamento de Farmacobiologia, CINVESTAV, Mexico City, Mexico
    Brain Res 1426:73-85. 2011
    ..administration of a glycogen synthase kinase (GSK3) inhibitor, lithium; antidementia drugs: phenserine and memantine, and insulin sensitizer, pioglitazone on memory function of ICV STZ-rats was assessed...
  68. pmc DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT
    Rob Jones
    Section of Old Age Psychiatry, The University of Nottingham, A Floor, South Block, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Trials 10:57. 2009
    ..drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD...
  69. ncbi Effect of memantine on resting state default mode network activity in Alzheimer's disease
    Marco Lorenzi
    Laboratory of Epidemiology, Neuroimaging and Telemedicine, Istituto di Ricerca e Cura a Carattere Scientifico San Giovanni di Dio Fatebenefratelli, Brescia, Italy
    Drugs Aging 28:205-17. 2011
    b>Memantine is an approved symptomatic treatment for moderate to severe Alzheimer's disease that reduces the excitotoxic effects of hyperactive glutamatergic transmission...
  70. ncbi Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy
    E Sherwood Brown
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 884, USA
    Biol Psychiatry 64:727-9. 2008
    ..Use of NMDA receptor antagonists to attenuate corticosteroid effects in humans has not been investigated. We examine the NMDA receptor antagonist memantine in patients receiving corticosteroids.
  71. ncbi Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine
    A E Busch
    Institut fur Physiologie, 72076 Tubingen, Germany
    Mol Pharmacol 54:342-52. 1998
    ..hOCT2, electrogenic transport of norepinephrine, histamine, dopamine, serotonin, and the antiparkinsonian drugs memantine and amantadine was demonstrated by tracer influx, tracer efflux, electrical measurements, or a combination...
  72. ncbi Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine
    P T Francis
    King s College London, Wolfson Centre for Age Related Diseases, London, UK
    Curr Mol Pharmacol 2:77-82. 2009
    ..For example, the NMDA receptor antagonist, memantine has been shown to improve cognition, function (activities of daily living, ADLs) and, more recently, agitation/..
  73. ncbi Pigment epithelium-derived factor up-regulation induced by memantine, an N-methyl-D-aspartate receptor antagonist, is involved in increased proliferation of hippocampal progenitor cells
    T Namba
    Department of Neurochemistry, National Institute of Neuroscience, Tokyo 187 8502, Japan
    Neuroscience 167:372-83. 2010
    b>Memantine is classified as an NMDA receptor antagonist. We recently reported that memantine promoted the proliferation of neural progenitor cells and the production of mature granule neurons in the adult hippocampus...
  74. ncbi Memantine in dementia: a review of the current evidence
    Nathan Herrmann
    Division of Geriatric Psychiatry, Sunnybrook Health Sciences Centre, Faculty of Medicine, University of Toronto, Canada
    Expert Opin Pharmacother 12:787-800. 2011
    ..Understanding the pathogenesis of AD and developing effective treatments is a public health imperative. Memantine is a low- to moderate-affinity, non-competitive NMDA receptor antagonist that is currently approved for the ..
  75. ncbi Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs
    H J Otton
    Centre for Integrative Physiology, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK
    Neuropharmacology 60:388-96. 2011
    Clinically, amantadine and memantine are drugs whose therapeutic utility is linked to their ability to block N-methyl-D-aspartate receptors (NMDARs) in a voltage-dependent manner...
  76. ncbi Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions
    Clive Ballard
    Wolfson Centre for Age Related Diseases, King s College London, London, UK
    Curr Opin Psychiatry 22:532-40. 2009
    ..The purpose of this review is to describe the current state of knowledge regarding management of BPSD, with a particular focus on agitation...
  77. ncbi Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain
    Gislaine Z Réus
    Laboratório de Neurociências and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina INCT TM, Programa de Pos Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, SC, 88806 000, Brazil
    J Neural Transm 119:481-91. 2012
    ..the creatine kinase and mitochondrial respiratory chain activities after acute and chronic treatments with memantine (N-methyl-D: -aspartate receptor antagonist) and imipramine (tricyclic antidepressant) in rats...
  78. ncbi Cognition-enhancing and anxiolytic effects of memantine
    Rimante Minkeviciene
    Department of Neurobiology, A I Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland
    Neuropharmacology 54:1079-85. 2008
    b>Memantine, a moderate-affinity NMDA receptor antagonist, is clinically used for the treatment of Alzheimer's disease (AD)...
  79. ncbi Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole
    R T Owen
    Drugs Today (Barc) 48:469-78. 2012
    ..Trials with memantine and riluzole, agents with actions broadly similar to and different from ketamine on the glutamatergic system, ..
  80. ncbi A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Curr Med Res Opin 26:263-9. 2010
    To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease receiving concomitant memantine.
  81. pmc Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial
    Michelle Petri
    Johns Hopkins University, Baltimore, MD 21205, USA
    Semin Arthritis Rheum 41:194-202. 2011
    ..b>Memantine, a seronergic receptor and nicotine acetylcholine receptor antagonist, acts on the glutamatergic system through ..
  82. ncbi Memantine potentiates hippocampal θ oscillations at a therapeutic dose in anesthetized mice: a mechanistic link to its cognitive-enhancing properties
    Simone Guadagna
    Neuroscience Drug Discovery, H Lundbeck A S, Ottiliavej 9, 2500 Valby, Denmark
    Neuropharmacology 62:2208-18. 2012
    b>Memantine is an uncompetitive, low-affinity NMDA receptor antagonist clinically used for the treatment of cognitive deficits in moderate to severe Alzheimer's disease...
  83. ncbi The NMDA antagonist memantine impairs classical eyeblink conditioning in humans
    M M Schugens
    Institute of Medical Psychology and Behavioral Neurobiology, University of Tubingen, Germany
    Neurosci Lett 224:57-60. 1997
    ..the effects of a single oral dose (30 mg) of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine on memory and learning in human subjects...
  84. ncbi Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine
    Falko Meisner
    Institute of Virology and Immunobiology, University of Wurzburg, Germany
    Neuropsychopharmacology 33:2228-36. 2008
    ..b>Memantine, an uncompetitive NMDA receptor antagonist, which has been recently approved for the treatment of Alzheimer's ..
  85. ncbi Memantine acts as a cholinergic stimulant in the mouse hippocampus
    Benjamin D Drever
    School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD Scotland, UK
    J Alzheimers Dis 12:319-33. 2007
    The non-competitive NMDA receptor antagonist memantine, currently prescribed for the treatment of Alzheimer's disease, is assumed to prevent the excitotoxicity implicated in neurodegenerative processes...
  86. pmc Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine
    Shawn E Kotermanski
    Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
    J Neurosci 29:2774-9. 2009
    ..1999). Memantine, a drug that blocks the ion channel formed by NMDARs, is a widely prescribed treatment of Alzheimer's disease (..
  87. ncbi Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
    Patrizia Mecocci
    Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy
    Int J Geriatr Psychiatry 24:532-8. 2009
    The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD.
  88. pmc Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice
    George M Alley
    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
    J Neurosci Res 88:143-54. 2010
    b>Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD)...
  89. pmc Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation
    Hung Ming Wu
    College of Medicine, Institute of Behavioral Medicine, National Cheng Kung University, Tainan, Taiwan
    Neuropsychopharmacology 34:2344-57. 2009
    b>Memantine shows clinically relevant efficacy in patients with Alzheimer's disease and Parkinson's disease...
  90. ncbi Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage
    Stuart A Lipton
    Center for Neuroscience and Aging, The Burnham Institute, University of California San Diego, La Jolla, California 92037, USA
    Surv Ophthalmol 48:S38-46. 2003
    ..Studies in our laboratory have shown that the adamantane derivative, memantine, blocks only excessive NMDA-receptor activity without disrupting normal activity...
  91. pmc Memantine for AIDS dementia complex: open-label report of ACTG 301
    Yu Zhao
    Harvard School of Public Health, Boston, Massachusetts, USA
    HIV Clin Trials 11:59-67. 2010
    To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment.
  92. ncbi Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures
    William A Hare
    Department of Biological Sciences, Allergan Inc, Irvine, California 92612, USA
    Invest Ophthalmol Vis Sci 45:2640-51. 2004
    To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates.
  93. ncbi Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
    Harish Kavirajan
    Department of General Internal Medicine, Division of Health Services Research, Veterans Affairs Greater Los Angeles Health Care System, CA, USA
    Lancet Neurol 6:782-92. 2007
    Cholinesterase inhibitors and memantine do not have regulatory approval in most of the world for treatment of vascular dementia...
  94. ncbi Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA
    JAMA 291:317-24. 2004
    b>Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist...
  95. ncbi Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees
    M Schley
    Department of Anaesthesiology and Intensive Care Medicine, Experimental Pain Research Pain Centre, University of Heidelberg, Faculty of Clinical Medicine, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Eur J Pain 11:299-308. 2007
    ..Hyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP)...
  96. ncbi Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study
    Giovanni Schifitto
    University of Rochester, Rochester, New York 14620, USA
    AIDS 21:1877-86. 2007
    To assess the safety and efficacy of memantine, an uncompetitive antagonist of the N-methyl-D-aspartate receptor as treatment of HIV-associated cognitive impairment.
  97. pmc Long-term course and effectiveness of combination therapy in Alzheimer disease
    Alireza Atri
    Department of Neurology and Massachusetts Alzheimer s Disease Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Alzheimer Dis Assoc Disord 22:209-21. 2008
    ..and long-term clinical trajectory in patients with Alzheimer disease (AD) treated with combination (COMBO) therapy consisting of cholinesterase-inhibitor (CI) plus memantine (MEM) versus CI alone versus no treatment with either.
  98. pmc Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells
    Balmiki Ray
    Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Neurosci Lett 470:1-5. 2010
    b>Memantine, an uncompetitive NMDA receptor antagonist, is a FDA-approved drug used for the treatment of moderate-to-severe Alzheimer's disease (AD)...
  99. ncbi Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial
    Jamie D Feusner
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
    Psychopharmacol Bull 42:81-93. 2009
    ..b>Memantine blocks the excitatory action of glutamate at the N-methyl- D-aspartate (NMDA) receptor under pathological ..
  100. ncbi Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain
    Robert J Hackworth
    Naval Medical Center San Diego, Department of Anesthesiology, 34800 Bob Wilson Drive, San Diego, CA 92134, USA
    Anesth Analg 107:1377-9. 2008
    ..Upon induction of the oral N-methyl-D-aspartate receptor antagonist memantine, both patients had a profound reduction in their PLP without any apparent side effects from the medication.
  101. pmc Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine
    Guohua Zhang
    Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129 2060, USA
    J Neurosci 28:4551-60. 2008
    ..Finally, we examined the effects of the NMDA receptor partial antagonist, memantine, in H4-APP cells and brain tissue of naive mice...

Research Grants62

  1. Preclinical Development of a Novel and Effective Treatment for Cough
    Blake M Paterson; Fiscal Year: 2011
    ..receptors and of the role of NMDA receptors in central cough gating mechanisms have led to the observation that memantine (MMT), a registered drug for the treatment of dementia, is a profound antitussive in animal models...
  2. The Functional Significance of Conformational States in Glutamatergic Signaling
    CATHERINE LOURDES SALUSSOLIA; Fiscal Year: 2013
    ..therapies available for clinical use, but those agents that are clinically useful (amantidine and memantine) share a common theme: they modulate NMDA receptor gating (opening/closing of the ion channel) in an activity-..
  3. Pilot Combination Treatment Trial of Mild Cognitive Impairment with Depression
    Davangere P Devanand; Fiscal Year: 2013
    ..In a second pilot study, open label es-citalopram plus memantine treatment led to a low rate of conversion to dementia...
  4. Attenuation of Corticosteroid-Induced Hippocampal Changes
    E Sherwood Brown; Fiscal Year: 2013
    ..We conducted a placebo-controlled proof-of-concept study of the NMDA receptor antagonist memantine in corticosteroid-treated patients and found statistically significant improvement in declarative memory...
  5. Role NR1/2C and NR1/2D NMDA Receptors in Cortex Function and Memantine Action
    Jon W Johnson; Fiscal Year: 2012
    ..NR1/2C and/or NR1/2D NMDARs play an especially important role in the clinical utility of the widely-used AD drug memantine, which is an antagonist of NMDARs...
  6. An iPS Disease-in-a-Dish Model of Familial Alzheimers
    Terrence Town; Fiscal Year: 2012
    ..Sub-Aim 2b will test proof-of-concept for whether the current standard of care AD drug, memantine, will at least partially rescue Alzheimer phenotype(s) in differentiated fAD mutant forebrain neurons...
  7. Development of a Novel Therapeutic for Alzheimer'Disease
    MARK ANTHONY LOVELL; Fiscal Year: 2012
    ..AD) patients including cholinesterase inhibitors (Aricept) and an N-methyl-D-aspartate (NMDA) antagonist (Memantine). Although these therapeutics show clinical benefit in some patients, many do not respond...
  8. INVESTIGATION AND TREATMENT OF OCULAR MOTOR DISORDERS
    RICHARD JOHN LEIGH; Fiscal Year: 2012
    ..A current model for these oscillations will be tested using detailed findings from a treatment trial of memantine versus gabapentin completed during the prior funding period...
  9. Novel NMDA Antagonists to Treat Stroke
    Bhaumik B Patel; Fiscal Year: 2013
    ..directly compare the pharmacological profiles of three novel NMDA antagonists, the uncompetitive NMDA antagonist memantine, which was recently approved for the treatment of Alzheimer's disease because of beneficial effects and a ..
  10. 2/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
    Dikoma C Shungu; Fiscal Year: 2013
    ..g., riluzole, memantine) reduce OCD severity when added to SRIs...
  11. 1/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
    Helen Blair Simpson; Fiscal Year: 2013
    ..g., riluzole, memantine) reduce OCD severity when added to SRIs...
  12. Brain aging and treatment response in geriatric depression
    Helen Lavretsky; Fiscal Year: 2013
    ..There is a compelling rationale for the study of neuroprotective glutamatergic agents, such as memantine (MEM) that can target brain aging and provide cognitive enhancement...
  13. Brief Potent Glutamatergic Modulation: Applications for Cocaine Dependence
    Elias Dakwar; Fiscal Year: 2013
    ..However, the only specific antagonist studied, memantine, failed to show an effect in humans...
  14. Roles and mechanisms of neurotensin in learning and memory
    Saobo Lei; Fiscal Year: 2013
    ..for the treatment of AD including the cholinesterase inhibitors and the partial NMDA receptor antagonist memantine only benefit a subset of patients for a limited period...
  15. Cellular/Molecular Pathophysiology of Intellectual and Developmental Disabilities
    Stuart A Lipton; Fiscal Year: 2013
    ..This P01 Grant is credited with developing the first clinically-tolerated NMDAR antagonist, Memantine, which we showed is an uncompetitive, open-channel blocker with a relatively fast off-rate, accounting for its ..
  16. NMDA Glutamate Receptor Transmission in Extinction of Cocaine-Seeking Behavior
    STANISLAV R contact VOREL; Fiscal Year: 2010
    ..approved for other human clinical conditions, the NMDA receptor agonist d-cycloserine and the NMDA antagonist memantine. We will assess if and how NMDA receptors are involved in extinction and if the medications have ..
  17. Memantine effects on sensorimotor gating and neurocognition in schizophrenia
    Neal R Swerdlow; Fiscal Year: 2013
    ..This application will test the effects of a "challenge dose" of the low-affinity NMDA antagonist, memantine (MEM), on sensorimotor gating and neuro- cognition in SZ patients;specific hypotheses will be tested in relation ..
  18. Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
    TODD DYLAN LEVINE; Fiscal Year: 2013
    ..Results from an open label pilot trial of 20 patients treated with memantine at 10 mg twice a day (BID) suggested that treatment with the combination of memantine and riluzole slowed ALS ..
  19. Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
    Neal R Swerdlow; Fiscal Year: 2013
    ..goals of this application are: 1) to test the effects of the acute administration of the NMDA antagonist, memantine (MEM), on sensorimotor gating and working memory (WM) in schizophrenia (SZ) patients, and 2) to assess the ..
  20. CORTICOLIMBIC DEGENERATION AND TREATMENT OF DEMENTIA
    John Csernansky; Fiscal Year: 2009
    ..S. Memantine, a voltage dependent, uncompetitive NMDA antagonist, ameliorates the cognitive deficits associated with ..
  21. NOVEL PHARMACOTHERAPIES FOR COCAINE DEPENDENCE
    Frances Levin; Fiscal Year: 2003
    ..To perturb the glutamate system, we will use memantine, a non-competitive NMDA antagonist GV-196771A, a glycine site antagonist; acamprosate, a partial agonist at the ..
  22. Retinal ganglion cell loss in aging mice.
    Thomas Mittag; Fiscal Year: 2007
    ..a beta-adrenergic antagonist, inhibitors of the NOS-2 enzyme, and the anti-Parkinson's agents deprenyl and memantine. The drug experiments are aimed at establishing proof-of-principle that agents having neuroprotective properties ..
  23. NOVEL NMDA RECEPTOR ANTAGONISTS FOR HIV NEUROINJURY
    Yuqiang Wang; Fiscal Year: 2000
    ..Stuart Lipton, Harvard Medical School, found that the clinically-tolerated NMDA antagonist memantine and nitric oxide (NO)-related species such as nitroglycerin (NTG) can protect neurons in mixed neuronal/glial ..
  24. ADVANCED MR SPECTROSCOPY OF SIV BRAIN INJURY
    Ramon Gonzalez; Fiscal Year: 2001
    ..In addition, some animals will be given the NMDA antagonist memantine. In other experiments, the animals will be treated after infection...
  25. BEHAVIORAL EFFECTS OF NEONATAL ALCOHOL EXPOSURE
    Edward P Riley; Fiscal Year: 2010
    ..We now plan on examining, memantine, a novel NMDA antagonist that seems to have few of the side effects of other NMDA antagonists, thus it may be ..
  26. Potential anti-relapse drugs: a plant genomics approach
    John Littleton; Fiscal Year: 2004
    The actions of acamprosate, memantine and mecamylamine in alcohol dependence suggest that glutamate receptors (specifically NMDARs and mGluRSs) and acetylcholine receptors (specifically nicAChRs) are potential molecular targets for ..
  27. DRUG ABUSE PHARMACOTHERAPY: METHODOLOGIC INITIATIVES
    Edward Nunes; Fiscal Year: 2005
    ..Cocaine medication development trials examining the efficacy of the NMDA antagonist memantine and the GABA enhancer gabapentin, and also examining the impact of abstinence during an initial placebo lead-in ..
  28. Novel Glutamatergic Detoxification Strategies
    John Krystal; Fiscal Year: 2006
    This is a resubmission of an R21 proposal. This pilot study will compare the effectiveness of the lamotrigine and memantine to standard treatment of acute alcohol withdrawal and abstinence initiation in alcohol dependent patients, and ..
  29. EVALUATION OF NMDA ANTAGONIST FOR OPIATE DEPENDENCE
    Adam Bisaga; Fiscal Year: 2003
    ..the research skills of Adam Bisaga, MD, by focusing on a systematic laboratory and clinical evaluation of memantine, an NMDA antagonist, for the treatment of opioid dependence. Dr...
  30. Novel NMDA Receptor-Binding Drugs for Ischemia/Stroke
    Yuqiang Wang; Fiscal Year: 2002
    ..Thus, we will combine a nitrone, known to have potent free radical scavenging activity with memantine, an open channel, uncompetitive NMDA receptor inhibitor, with demonstrated neuroprotective benefit in human ..
  31. INDUCTION OF APOPTOSIS BY HIV-1 INFECTED MONOCYTIC CELLS
    Lloyd Mayer; Fiscal Year: 2007
    ..receptor (MW 100 kDa) for SHIVA and have also demonstrated that SHIVA-induced apoptosis can be blocked by memantine in SH-SY5Y neuronal cells...
  32. Erythropoietin PLUS IGF-IN NEUROPROTECTION FROM AIDS
    Stuart Lipton; Fiscal Year: 2009
    ..Hypothesis Tested: EPO+IGF-I act synergistically to activate the anti-apoptotic PI3 kinase/Akt signaling pathway, and thus provide a synergistic degree of neuroprotection. ..
  33. AIDS-Related Neurotoxicity and Novel NMDAR Antagonists
    Stuart Lipton; Fiscal Year: 2009
    ..Also, this grant helped develop the first clinically-tolerated NMDAR antagonist, Memantine, which led to phase 2 clinical trials for HIV-associated dementia...
  34. ERYTHROPOIETIN-INDUCED NEUROPROTECTION
    Stuart Lipton; Fiscal Year: 2005
    ....
  35. Caspase Cleavage of MEF2 Mediates Neuronal Apoptosis
    Stuart Lipton; Fiscal Year: 2007
    ....
  36. Chemokines and Macrophages in HIV Neuronal Apoptosis
    Stuart Lipton; Fiscal Year: 2003
    ..Neuronal apoptosis due to gp120 or chemokines will be monitored using several approaches. ..
  37. S-Nitrosylation of Matrix Metalloproteinases in AIDS
    Stuart Lipton; Fiscal Year: 2007
    ..In the future, the work proposed here may lead to new therapeutic targets based on the novel extracellular signaling pathway involving NO-related molecules and the MMPs that will be studied. ..
  38. RETINAL GANGLION CELLS: ION CHANNELS & TRANSMITTERS
    Stuart A Lipton; Fiscal Year: 2010
    ..Our group was the first to show that the uncompetitive, open-channel blocker, Memantine, can curtail excessive activity of the NMDAR while leaving normal neurotransmission essentially unabated...
  39. Depression in Alzheimer's Disease Study 2 (DIADS-2)
    Lon Schneider; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  40. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  41. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
    Christopher H van Dyck; Fiscal Year: 2010
    ..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..
  42. Dronabinol naltrexone treatment for opioid dependence
    Adam Bisaga; Fiscal Year: 2010
    ..Development of an improved antagonist based approach would open it up as a viable treatment alternative for a larger population of opioid dependent individuals. ..
  43. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
    ....
  44. Developing Medication For Tobacco Addiction: NMDA Agents
    Adam Bisaga; Fiscal Year: 2007
    ..models to screen promising medications and establish whether modulation of the NMDA receptor system with memantine, a non-competitive NMDA antagonist, has beneficial effects in the treatment of tobacco addiction...
  45. Cognitive-Behavioral Therapy for Pathological Gambling
    Jon Grant; Fiscal Year: 2008
    ..This award would provide me with the necessary background for further studies in the treatment of pathological gambling and the training for an independent patient-oriented research career. ..
  46. AGING AND DEMENTIA--LONGITUDINAL COURSE OF SUBGROUPS
    Barry Reisberg; Fiscal Year: 2002
    ..Collectively, these cohorts include over 1300 persons. The comprehensive evaluations include behavioral, mental status, neuropsychologic, neurologic, neuroimaging, electrophysiologic, and postmortem studies. ..
  47. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  48. Treatment Outcomes of Vascular Depression
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..The proposed trial will provide information of value to the practitioner and also provide data to build a more comprehensive model of the prognostic impact of frontal-subcortical brain changes on the outcome of late-life depression. ..
  49. Memantine Naltrexone Treatment for Opioid Dependence
    Adam Bisaga; Fiscal Year: 2009
    ..The goal of this five-year study is to test the efficacy of memantine (a noncompetitive NMDA receptor antagonist) as an adjunct to the maintenance treatment with naltrexone in ..
  50. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006
    ..Alcohol use is the primary outcome, and alcohol craving is the secondary outcome. Manic and depressive symptom severity and the relationship between changes in alcohol use and changes in mood will be expIored. ..
  51. Development of Inventory of Depressive Symptomatology
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..
  52. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2003
    ..The proposed study will take advantage of the ACTG supporting A5090 study and of the existing MRS consortium infrastructure that will allow us to perform multicenter MRS studies. ..
  53. Depressoin in Alzheimer's Disease Study-2 (DIADS-2)
    Jacobo Mintzer; Fiscal Year: 2007
    ..abstract_text> ..
  54. AGE RELATED NEURODEGENERATIVE DISEASES IN MICRONESIA
    Douglas Galasko; Fiscal Year: 2006
    ..Subproject by Lee: 'PHF-tau in neurodegenerative diseases of Guam' will assess oxidative markers related to brain lesions in ALS, PDC and dementia. ..
  55. Pain Mechanisms and the Development of Analgesics
    Tony Yaksh; Fiscal Year: 2006
    ..g. COX2 inhibitors, GABApentin, ziconotide) and failures (NK1 antagonist). [unreadable] [unreadable] [unreadable]..
  56. BRAIN MRI & MRS CHANGES IN FIRST EPISODE SCHIZOPHRENIA
    Jeffrey Lieberman; Fiscal Year: 2004
    ..This study will provide important information about the clinical and neuropathological course of subgroups of schizophrenia and therapeutic strategies for early identification and intervention. ..
  57. Mechanisms of Basal Forebrain Neurodegeneration
    LUIS COLOM; Fiscal Year: 2004
    ..Data from this work may contribute to the development of specific therapies designed to decrease neuronal dysfunction and vulnerability in AD. Furthermore, this work will contribute to our understanding of basal forebrain physiology. ..
  58. TREATMENT OF EARLY ONSET SCHIZOPHRENIA SPECTRUM (TEOSS)
    Robert Findling; Fiscal Year: 2005
    ..This study will provide information about the comparative effectiveness of the most commonly used and representative antipsychotic drugs in youth with schizophrenia spectrum disorders. ..
  59. Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans
    Sandra D Comer; Fiscal Year: 2010
    ....
  60. Ethanol sensitivity--native /recombinant NMDA receptors
    John Woodward; Fiscal Year: 2006
    ..The successful completion of this training plan will substantially enhance the PI's research expertise and his ability to fulfill the goals of his research. ..